Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome
diseaseOn this page
Also known as HLTRS
Summary
Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome (MONDO:0019073) is a disease caused by SOX18 (GenCC Strong), with 1 cohort gene.
At a glance
- Causal gene: SOX18 (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 69
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hypotrichosis-lymphedema-telangiectasia-renal defect syndrome |
| Mondo ID | MONDO:0019073 |
| MeSH | C536825 |
| OMIM | 137940 |
| DOID | DOID:0111360 |
| UMLS | C4317151 |
| MedGen | 1373459 |
| GARD | 0002492 |
| Is cancer (heuristic) | no |
Also known as: HLTRS · hypotrichosis-lymphedema-telangiectasia-renal defect syndrome
Data availability: 69 ClinVar variants · 4 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › syndromic disease › hypotrichosis-lymphedema-telangiectasia syndrome (grouping) › hypotrichosis-lymphedema-telangiectasia-renal defect syndrome
Related subtypes (1): hypotrichosis-lymphedema-telangiectasia syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
69 retrieved; paginated sample, class counts are floors:
57 uncertain significance, 5 conflicting classifications of pathogenicity, 3 likely benign, 2 likely pathogenic, 1 benign/likely benign, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 433539 | NM_018419.3(SOX18):c.712G>T (p.Glu238Ter) | SOX18 | Pathogenic | criteria provided, single submitter |
| 3587628 | NM_018419.3(SOX18):c.917_947del (p.Leu306fs) | SOX18 | Likely pathogenic | criteria provided, single submitter |
| 8002 | NM_018419.3(SOX18):c.720C>A (p.Cys240Ter) | SOX18 | Likely pathogenic | criteria provided, single submitter |
| 2070559 | NM_018419.3(SOX18):c.853G>C (p.Gly285Arg) | SOX18 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 2534625 | NM_018419.3(SOX18):c.93C>G (p.Asp31Glu) | SOX18 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 2743162 | NM_018419.3(SOX18):c.553G>C (p.Glu185Gln) | SOX18 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 3587651 | NM_018419.3(SOX18):c.359-14C>G | SOX18 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 872265 | NM_018419.3(SOX18):c.911C>A (p.Pro304Gln) | SOX18 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 3237434 | NM_018419.3(SOX18):c.166C>T (p.Arg56Cys) | LOC130066420 | Uncertain significance | criteria provided, single submitter |
| 3587658 | NM_018419.3(SOX18):c.123_140dup (p.Ala47_Pro48insLeuAlaAlaProAlaAla) | LOC130066420 | Uncertain significance | criteria provided, single submitter |
| 2039484 | NM_018419.3(SOX18):c.961G>A (p.Asp321Asn) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2069138 | NM_018419.3(SOX18):c.71C>A (p.Pro24Gln) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2076665 | NM_018419.3(SOX18):c.112G>T (p.Gly38Cys) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2148873 | NM_018419.3(SOX18):c.601C>T (p.Pro201Ser) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2196021 | NM_018419.3(SOX18):c.853G>A (p.Gly285Ser) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2231776 | NM_018419.3(SOX18):c.664G>C (p.Gly222Arg) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2380634 | NM_018419.3(SOX18):c.548C>T (p.Pro183Leu) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2474772 | NM_018419.3(SOX18):c.88G>T (p.Ala30Ser) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2516120 | NM_018419.3(SOX18):c.812G>A (p.Arg271Lys) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2609961 | NM_018419.3(SOX18):c.748G>A (p.Ala250Thr) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2848825 | NM_018419.3(SOX18):c.940C>A (p.Pro314Thr) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2902243 | NM_018419.3(SOX18):c.134C>T (p.Pro45Leu) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3007794 | NM_018419.3(SOX18):c.797T>G (p.Leu266Arg) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3167754 | NM_018419.3(SOX18):c.964G>T (p.Val322Leu) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3321629 | NM_018419.3(SOX18):c.1031C>T (p.Pro344Leu) | SOX18 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3346851 | NM_018419.3(SOX18):c.800C>G (p.Ala267Gly) | SOX18 | Uncertain significance | criteria provided, single submitter |
| 3587623 | NM_018419.3(SOX18):c.1151G>T (p.Gly384Val) | SOX18 | Uncertain significance | criteria provided, single submitter |
| 3587624 | NM_018419.3(SOX18):c.1130A>G (p.Tyr377Cys) | SOX18 | Uncertain significance | criteria provided, single submitter |
| 3587625 | NM_018419.3(SOX18):c.1087A>T (p.Ser363Cys) | SOX18 | Uncertain significance | criteria provided, single submitter |
| 3587626 | NM_018419.3(SOX18):c.1069A>G (p.Met357Val) | SOX18 | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 10 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| SOX18 | Strong | Autosomal dominant | hypotrichosis-lymphedema-telangiectasia-renal defect syndrome | 10 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| SOX18 | Orphanet:69735 | Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| SOX18 | HGNC:11194 | ENSG00000203883 | P35713 | Transcription factor SOX-18 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| SOX18 | Transcription factor SOX-18 | Transcriptional activator that binds to the consensus sequence 5’-AACAAAG-3’ in the promoter of target genes and plays an essential role in embryonic cardiovascular development and lymphangiogenesis. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Transcription factor | 1 | 8.3× | 0.121 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| SOX18 | Transcription factor | no | HMG_box_dom, Sox_C, Sox7/17/18_central |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| apex of heart | 1 |
| left uterine tube | 1 |
| right lung | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| SOX18 | 165 | broad | marker | apex of heart, right lung, left uterine tube |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| SOX18 | 1,525 |
Structural data
PDB: 0 · AlphaFold-only: 1 · No structure: 0
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| SOX18 | P35713 | 63.44 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| stem cell fate specification | 1 | 4213.0× | 0.002 | SOX18 |
| endocardium formation | 1 | 4213.0× | 0.002 | SOX18 |
| hair cycle process | 1 | 2808.7× | 0.002 | SOX18 |
| endocardial cell differentiation | 1 | 2808.7× | 0.002 | SOX18 |
| lymphatic endothelial cell differentiation | 1 | 2407.4× | 0.002 | SOX18 |
| blood vessel endothelial cell migration | 1 | 1404.3× | 0.002 | SOX18 |
| regulation of stem cell proliferation | 1 | 1404.3× | 0.002 | SOX18 |
| lymphangiogenesis | 1 | 1203.7× | 0.002 | SOX18 |
| vasculature development | 1 | 1123.5× | 0.002 | SOX18 |
| embryonic heart tube development | 1 | 766.0× | 0.003 | SOX18 |
| establishment of endothelial barrier | 1 | 766.0× | 0.003 | SOX18 |
| cell maturation | 1 | 443.5× | 0.004 | SOX18 |
| hair follicle development | 1 | 383.0× | 0.004 | SOX18 |
| outflow tract morphogenesis | 1 | 306.4× | 0.005 | SOX18 |
| heart looping | 1 | 267.5× | 0.005 | SOX18 |
| vasculogenesis | 1 | 255.3× | 0.005 | SOX18 |
| in utero embryonic development | 1 | 72.0× | 0.018 | SOX18 |
| angiogenesis | 1 | 62.4× | 0.020 | SOX18 |
| negative regulation of DNA-templated transcription | 1 | 31.6× | 0.037 | SOX18 |
| positive regulation of DNA-templated transcription | 1 | 27.9× | 0.039 | SOX18 |
| negative regulation of transcription by RNA polymerase II | 1 | 17.7× | 0.059 | SOX18 |
| positive regulation of transcription by RNA polymerase II | 1 | 14.9× | 0.067 | SOX18 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| SOX18 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| SOX18 | 11 | Binding:11 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | SOX18 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| SOX18 | 11 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: SOX18